Daniel S. Lorrain, Chief Scientific Officer at Contineum Therapeutics, Inc. (CTNM), sold 12,281 shares at $16.37 ($201K) on 2024-11-18, disclosed to the SEC on 2024-11-20.
Scheduled sale ($201k) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $16.37 | 6,091 | $100K | 49.6% |
| 2 | $16.37 | 6,091 | $100K | 49.6% |
| 3 | $17.05 | 99 | $2K | 0.8% |
| Total | $16.38 avg | 12,281 | $201K | 100% |
| Filing → |
| CTNM | SELL | 2026-06-01 | $55K | — | Filing → |
| CTNM | SELL | 2026-05-01 | $55K | — | Filing → |
| CTNM | SELL | 2026-04-06 | $56K | — | Filing → |